Pediatric experience with extracorporeal photochemotherapy (ECP) for graft-versus-host disease (GvHD) has mainly been reported by Italian and French groups. Data concerning 41 children with acute GvHD and 63 children affected by chronic GvHD are available. In 73 and 63% of them, respectively, improvement was observed, with addition of ECP to their immunosuppressive regimen. Treatment with ECP was associated with minimal side effects, even in the smallest of patients. In all responded pediatric patients, both with acute and chronic GvHD, ECP allowed progressive reduction or discontinuation of the concomitant pharmacological immunosuppressive therapy without an increase in GvHD acitivity. These data show that ECP is a useful therapy for children affected by GvHD resistant to conventional treatment and can be safely used. Bone Marrow Transplantation (2005) 35, S69-S71.
graft-versus-host disease
Extracorporeal photochemotherapy (ECP), based on the immunomodulating action of UV-A irradiation on blood mononuclear cells collected by apheresis and photosensitized by 8-methoxypsoralen , is an alternative therapeutic modality for graft-versus-host disease (GvHD) treatment. Although its exact mechanism of action is not fully understood (several cellular/cytokine changes were demonstrated) and results of randomized studies are not yet available, worldwide experience with ECP for GvHD has grown enormously over the past decade.
Pediatric experience with ECP for GvHD (to date, results on about 100 children treated are available) has mainly been reported by Italian [1] [2] [3] [4] [5] [6] [7] [8] [9] and French [10] [11] [12] [13] [14] [15] groups. Most of this has been in the form of case reports or small series. The largest cohorts are two retrospective studies: one multicenter Italian (77 patients) 9 and one French monocenter experience (20 patients). 15 With this overview, we would like to shine some light on ECP in the treatment of GvHD in children, a subject that is perhaps little or poorly understood but which definitely merits attention.
For the indication and eligibility for ECP treatment there are some consensual criteria (GvHD not responding to 'conventional treatment', no concomitant treatment with ALG/ATG or monoclonal antibodies causing lymphocytes lysis, complete hematological remission), and some questions, such as the number of circulating lymphocytes, and whether there was stable engraftment. For acute GvHD, the situation is relatively clear as there exists a definition for the nonresponse after 1 week of steroid therapy. For chronic GvHD, the variability in the definition of nonresponding disease is an important factor of confusion that affects evaluation.
Also, the timing-schedule of ECP treatment in GvHD is still under discussion. Once again, a certain degree of consensus exists: (1) treatment schedules for acute GvHD with a single-day treatment three times a week or 2 consecutive days once a week, at the beginning, (2) progressive tapering for both acute and chronic disease. Over the last few years, treatment intensification has been explored in patients recently enrolled when compared to earlier patients. Moreover, a better outcome seems to be associated with ECP given early after the onset of disease. However, many questions about treatment duration and total number of sessions remain.
Two techniques are currently used with considerably more patients treated by Cobe Spectra and Uvamatic than by Therakos (69 vs 33 patients reported). This could be explained by minimization of the extracorporeal volume and shortening of the time of a sedentary period of procedure (collection), which are of importance in the pediatric context.
The main difficulties in ECP role's assessment in published clinical trials are: (1) marked heterogeneity of patients enrolled, specially for chronic disease, because of no agreed definition of 'nonresponding GvHD'; (2) a large variability in timing between the onset of disease and the start of ECP; (3) different treatment protocols and schedules; (4) heterogeneicity of concomitant immunosuppressive treatment.
For acute GvHD, data concerning 41 children were used. 2, 4, 6, 8, 9, 11, 14, 15, 17 In 73% of them, improvement was observed, with addition of ECP to their immunosuppressive regimen. A maximal response was observed after 10-15 ECP (1-2 months of treatment). 6, 9, 15 The best responders to ECP were children with skin manifestations (80%), whereas the rate of response of visceral involvement was lower (gut and liver improvement in 64 and 59% of patients, respectively) and less consistent.
Data of 63 children affected by chronic GvHD are available. [1] [2] [3] [4] 6, 8, 9, [12] [13] [14] [15] [16] The overall response was 63%. In 37% of patients, chronic GvHD was stable, or worsened. ECP provides excellent improvement in skin conditions, particularly on inflammatory lesions. Moreover, improvement in patients with scleroderma-like lesions and joint involvement has been observed. After ECP treatment, the quality of life and Karnofsky performance scores of the affected pediatric patients significantly improved. Complete or partial resolution of liver disease was seen in 73% of children. Improvement of gut and lung involvement was observed in 59 and 47% of patients, respectively. It is noteworthy that children responding to ECP described a significant subjective improvement and a better general feeling of well-being, as was reported in adult series (Table 1) .
Like in adults, in all responded pediatric patients, both with acute and chronic GvHD, EPC allowed progressive reduction or discontinuation of the concomitant pharmacological immunosuppressive therapy without an increase in GvHD activity. 6, 9, 13, 15 Treatment with EPC was associated with minimal side effects, even in the smallest of patients. Extracorporeal apheresis caused some episodes of hypotension, which, however, were only rarely symptomatic. No signs of citrate toxicity or metabolic complications were noted. [1] [2] [3] 6, 9, [13] [14] [15] None of the patients had profound thrombocytopenia or anemia. However, an increase of RBC transfusion demand was observed, particularly in patients with acute GvHD 6, 9 The management of transfusional demand may improve by processing fewer blood volumes and the progressive mastering of the ECP technique. No child experienced life-threatening bloodstream infections related to the procedure. 6, 9, 13, 15 Reactivation of human CMV infection was comparable to that of pediatric patients with acute GvHD, who did not receive ECP. 6, 9 So far, only a little information is available on the longterm follow-up of pediatric patients after ECP treatment. As far as patients with acute GvHD are concerned, followup ranges between 1 and 25 months. In all, 14 of 33 Italian and four of seven French patients died of GvHD (12 patients), relapse (two patients) or infection (four patiens). 2, 4, 6, 8, 9, 11, 13, 15 For children with chronic GvHD, follow-up ranges between 10 and 153 months with 77 and 85% of patients alive in the Italian and French series, respectively. The majority of surviving patients have a good quality of life, normal school and sport activity.
In conclusion, published data show that EPC is a useful therapy for children affected by GvHD resistant to conventional treatment and can be safely used even in children with low body weight and a poor performance status when the procedure is performed by an experienced pediatric team. Of note, the response to ECP is observed earlier than in other diseases such as CTCL with most children improving after few procedures.
Therefore, what could be the place of ECP in the pediatric setting today? In the light of the work of Francise Foss and her Boston group, 18 it would be very exciting to evaluate the possibility of ECP use as GvHD profilaxis. All paediatric data suggest that ECP in acute GvHD could be introduced early in the course of the disease (as the last 'agent' of the first line therapy, or as the first 'agent' of the second line therapy). To date, there have been no reported effects of ECP on the establishment of the graft, but this remains an ongoing question, as this therapy becomes more widely used in the early peritransplant period. As for acute GvHD, a precocious treatment with ECP is associated with a better prognosis also in chronic GvHD. In this setting, a patient-tailored length of treatment should be considered because in these patients the improvement is often low and the amelioration of cutaneous manifestations require more than 1 year to disappear. Moreover, the possibility of reduction of immunosuppressive therapy with its wellknown side effects in children is appealing. Prospective randomized clinical trials to assess the proper place of ECP in the GvHD prophylaxis and treatment in pediatric patients are urgently needed.
